10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments
SATISFACTION GUARANTEE: Satisfied customers are important to us
Maintain Realistic Expectations Skin improvements take time
Retrieved from Wharton, S., Davies, M., Dicker, D., et al
SW: So the Claudia I know thats biking, running, training hard, if you want to be 120 pounds then eat 120 grams of protein a day or at least 96 grams
10.1016/S0076-6879(05)01011-6 Methods Enzymol
